Literature DB >> 29198343

Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.

Pierluigi Bonomo1, Mauro Loi2, Isacco Desideri2, Emanuela Olmetto2, Camilla Delli Paoli2, Francesca Terziani2, Daniela Greto2, Monica Mangoni2, Silvia Scoccianti2, Gabriele Simontacchi2, Giulio Francolini2, Icro Meattini2, Saverio Caini3, Lorenzo Livi2.   

Abstract

PURPOSE: Radiotherapy plus cetuximab is an effective combination therapy for locally advanced head and neck squamous cell carcinoma. The aim of our study was to determine the frequency of skin toxicity in patients receiving the combined treatment.
RESULTS: Forty-eight studies were included in our analysis, for a total of 2152 patients. The mean rates of G3/G4 radiation dermatitis and acneiform rash were 32.5% (SD: 20.4; 95% CI: 28.5-36.5) and 13.4% (SD: 11.5; 95% CI: 11.2-15.6), respectively. The majority of studies referred to CTCAE scales for reporting both side effects (85.7% and 92.1%, respectively). Data on the management of skin toxicity were available in only 35.4% of the reviewed literature.
CONCLUSIONS: severe radiation dermatitis is a frequent side effect induced by the combination of radiotherapy and cetuximab in head and neck cancer. The lack of predictive biomarkers of toxicity hampers the possibilty to design preventive measures on a personalized basis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cetuximab; Dermatitis; Head and neck cancer; Radiotherapy; Rash

Mesh:

Substances:

Year:  2017        PMID: 29198343     DOI: 10.1016/j.critrevonc.2017.10.011

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  16 in total

1.  The effectiveness and safety of X-PDT for cutaneous squamous cell carcinoma and melanoma.

Authors:  Lei Shi; Pei Liu; Jing Wu; Lun Ma; Han Zheng; Michael P Antosh; Haiyan Zhang; Bo Wang; Wei Chen; Xiuli Wang
Journal:  Nanomedicine (Lond)       Date:  2019-06-05       Impact factor: 5.307

2.  Unseiin, a Kampo medicine, Reduces the Severity and Manifestations of Skin Toxicities Induced by Cetuximab: A Case Report.

Authors:  Kenkichiro Taira; Kazunori Fujiwara; Takahiro Fukuhara; Tsuyoshi Morisaki; Satoshi Koyama; Ryohei Donishi; Hiromi Takeuchi
Journal:  Yonago Acta Med       Date:  2020-11-24       Impact factor: 1.641

Review 3.  Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.

Authors:  Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi
Journal:  Nat Rev Clin Oncol       Date:  2021-11-24       Impact factor: 66.675

4.  EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.

Authors:  Sui-Whi Jane; Shu-Ching Chen; Ting-Yu Chiang; Hung-Chih Hsu
Journal:  Support Care Cancer       Date:  2020-01-23       Impact factor: 3.603

Review 5.  Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.

Authors:  Joana Caiado; Mariana C Castells
Journal:  Curr Allergy Asthma Rep       Date:  2021-07-07       Impact factor: 4.806

6.  Feasibility single-arm study of a medical device containing Desmodium adscendens and Lithothamnium calcareum combined with chemotherapy in head and neck cancer patients.

Authors:  Luca Imperatori; Damiano Giardini; Gino Latini; Giuseppe Migliori; Claudio Blasi; Feisal Bunkheila; Cesare Breschi; Rodolfo Mattioli; Silvia Pelliccioni; Carmen Laurino; Maria Vadalà; Beniamino Palmieri; Tommaso Iannitti
Journal:  Cancer Manag Res       Date:  2018-11-08       Impact factor: 3.989

Review 7.  Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity.

Authors:  Ganiou Assani; Yudi Xiong; Fuxiang Zhou; Yunfeng Zhou
Journal:  Oncotarget       Date:  2018-10-09

Review 8.  Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response.

Authors:  Mahmoud Toulany
Journal:  Genes (Basel)       Date:  2019-01-04       Impact factor: 4.096

9.  Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.

Authors:  Sacha I Rothschild; Daniel Betticher; Reinhard Zenhäusern; Sandro Anchisi; Roger von Moos; Miklos Pless; Peter Moosmann; Razvan A Popescu; Antonello Calderoni; Marco Dressler; Daniel Rauch; Stefanie Pederiva; Regina Woelky; Claudia Papet; Vera Bühler; Markus Borner
Journal:  Cancer Chemother Pharmacol       Date:  2019-08-23       Impact factor: 3.333

10.  The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy.

Authors:  L F J Huiskamp; N Chargi; L A Devriese; P A de Jong; R de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-04-25       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.